Dendrimer delivery system and methods of use thereof
Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.
1. A dendrimer comprising a central core, one or more branching units,
and a plurality of terminal hydroxyl groups,
wherein the dendrimer is a generation 2 dendrimer having a surface density of the hydroxyl groups of at least three hydroxyl groups/nm 2 , as measured by dynamic light scattering,
wherein the central core is prepared from one or more compounds selected from the group consisting of dipentaerythritol, azide-modified dipentaerythritol, alkyne-modified dipentaerythritol, pentaerythritol, azide-modified pentaerythritol, and alkyne-modified pentaerythritol,
wherein the one or more branching units comprise a linear or branched polyethylene glycol,
wherein one or more prophylactic, therapeutic, or diagnostic agents are encapsulated in, associated with, or conjugated to the dendrimer, and the dendrimer is formulated for systemic administration for local treatment of inflammation mediated by activated macrophages or microglia.
2. The dendrimer of claim 1 , wherein the surface density of the hydroxyl groups is at least four hydroxyl groups/nm 2 .
3. The dendrimer of claim 1 , wherein the surface density of the hydroxyl groups is between about 4 and about 15 hydroxyl groups/nm 2 .
4. The dendrimer of claim 1 , wherein the dendrimer has a molecular weight between about 500 Daltons and about 100,000 Daltons.
5. The dendrimer of claim 1 , wherein the dendrimer has a molecular weight between about 500 Daltons and about 50,000 Daltons.
6. The dendrimer of claim 1 , wherein the dendrimer has a molecular weight between about 1,000 Daltons and about 10,000 Daltons.
7. The dendrimer of claim 1 , wherein the dendrimer has a hydrodynamic diameter between about 1 nm and about 15 nm.
8. The dendrimer of claim 1 , wherein the dendrimer has a hydrodynamic diameter between about 1 nm and about 5 nm.
9. The dendrimer of claim 1 , wherein the dendrimer has a hydrodynamic diameter between about 1 nm and about 2 nm.
10. The dendrimer of claim 1 , wherein the central core is prepared from alkyne-modified dipentaerythritol.
11. The dendrimer of claim 1 , wherein the one or more branching units are prepared from a linear or branched polyethylene glycol of the following formula:
wherein:
n is 1-300; and
X is selected from the group consisting of amine, acid, aldehyde, alcohol, acetylene, allyl, acrylate, azide, tosyl, mesylate, thiol, N-hydroxy succinimide activated acid, and maleimide.
12. The dendrimer of claim 1 , wherein the dendrimer is of the following formula:
13. The dendrimer of claim 1 , wherein the dendrimer is in the form of a dendron.
14. The dendrimer of claim 1 , comprising multiple dendrimers organized into tectodendrimers.
15. The dendrimer of claim 1 , comprising one or more prophylactic, therapeutic, or diagnostic agents conjugated to the dendrimer.
16. The dendrimer of claim 1 , wherein the one or more prophylactic, therapeutic, or diagnostic agents are encapsulated in, associated with, or conjugated to the dendrimer at a concentration of between about 0.01% and about 30%.
17. The dendrimer of claim 1 , wherein the one or more prophylactic, therapeutic, or diagnostic agents are covalently conjugated to the dendrimer, via one or more spacers.
18. The dendrimer of claim 1 , wherein the one or more prophylactic, therapeutic, or diagnostic agents are covalently conjugated to the dendrimer via one or more linkages selected from the group consisting of disulfide, ester, ether, thioester, carbamate, carbonate, hydrazine, and amide linkages.
19. The dendrimer of claim 17 , wherein the spacer is a prophylactic, therapeutic, or diagnostic agent.
20. The dendrimer of claim 19 , wherein the spacer is N-acetyl cysteine.
21. The dendrimer of claim 1 , wherein the one or more therapeutic agents are selected from the group consisting of anti-inflammatory drugs, chemotherapeutics, vasodilators, and anti-infective agents.
22. A method for treating, preventing, or imaging one or more diseases, conditions, or injuries of the eye, the brain or the nervous system comprising administering to a subject in need thereof the dendrimers of claim 1 , wherein the dendrimers are in an amount effective to treat or alleviate one or more symptoms of the one or more diseases, conditions, or injuries of the eye, the brain or the nervous system.
23. The method of claim 22 , wherein the one or more diseases, conditions, or injuries of the eye, the brain or the nervous system are diseases, conditions, and injuries associated with activated microglia and astrocytes.
24. The method of claim 22 , wherein the dendrimers are in an amount effective to target activated microglia and astrocytes.
25. The method of claim 22 , wherein the dendrimers are in an amount effective to treat or alleviate one or more symptoms of one or more diseases, conditions, or injuries of the brain or nervous system.
26. The method of claim 22 , wherein the dendrimers are administered intravenously.
27. The dendrimer of claim 16 , wherein the dendrimer is complexed or conjugated to one or more therapeutic, prophylactic, or diagnostic agents at a concentration of between about 1% and about 20%.
28. The dendrimer of claim 1 , wherein the activated macrophages are resident macrophage cells of the central nervous system.